-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, E3rejetCOY11uyyjfsDVBv/UCXfSm5Qv+zqFBKpuToRKLadt2dJAs1lciG5GgA8f Q0fK+K2+1uPGebhQwiYPkQ== 0001144204-04-001334.txt : 20040212 0001144204-04-001334.hdr.sgml : 20040212 20040212171532 ACCESSION NUMBER: 0001144204-04-001334 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20040212 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: INDEVUS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000854222 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043047911 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-41015 FILM NUMBER: 04592756 BUSINESS ADDRESS: STREET 1: ONE LEDGEMONT CENTER STREET 2: 99 HAYDEN AVE CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 6178618444 MAIL ADDRESS: STREET 1: ONE LEDGEMONT CENTER STREET 2: 99 HAYDEN AVE CITY: LEXINGTON STATE: MA ZIP: 02421 FORMER COMPANY: FORMER CONFORMED NAME: INTERNEURON PHARMACEUTICALS INC DATE OF NAME CHANGE: 19920703 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: ROSENWALD LINDSAY A MD CENTRAL INDEX KEY: 0000941841 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 375 PARK AVE STREET 2: SUITE 1501 CITY: NEW YORK STATE: NY ZIP: 10152 BUSINESS PHONE: 2128324366 MAIL ADDRESS: STREET 1: 375 PARK AVE CITY: NEW YORK STATE: NY ZIP: 10152 FORMER COMPANY: FORMER CONFORMED NAME: ROSENWALD LINDSAY MD DATE OF NAME CHANGE: 19950316 SC 13G/A 1 v01559_indevus13ga.txt SCHEDULE 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 4) Under the Securities Exchange Act of 1934 Indevus Pharmaceuticals, Inc Common Stock, no par value per share (Title of Class of Securities) 454072109 CUSIP Number December 31, 2003 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |_| Rule 13d-1(b) |X| Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). Continued on following pages Page 1 of 5 Pages SCHEDULE 13G CUSIP No. 454072109 Page 2 of 5 - -------------------------------------------------------------------------------- 1 Names of Reporting Persons I.R.S. Identification Nos. of above persons (entities only) LINDSAY A. ROSENWALD, M.D. - -------------------------------------------------------------------------------- 2 Check the Appropriate Box If a Member of a Group * a. |_| b. |X| - -------------------------------------------------------------------------------- 3 SEC Use Only - -------------------------------------------------------------------------------- 4 Citizenship or Place of Organization UNITED STATES - -------------------------------------------------------------------------------- 5 Sole Voting Power Number of 3,078,463 Shares -------------------------------------------------------------- Beneficially 6 Shared Voting Power Owned By 0 Each -------------------------------------------------------------- Reporting 7 Sole Dispositive Power Person 3,078,463 With -------------------------------------------------------------- 8 Shared Dispositive Power 0 - -------------------------------------------------------------------------------- 9 Aggregate Amount Beneficially Owned by Each Reporting Person 3,078,463 - -------------------------------------------------------------------------------- 10 Check Box If the Aggregate Amount in Row (9) Excludes Certain Shares * |_| - -------------------------------------------------------------------------------- 11 Percent of Class Represented By Amount in Row (9) 6.47% - -------------------------------------------------------------------------------- 12 Type of Reporting Person * IN - -------------------------------------------------------------------------------- * see instructions before filling out CUSIP No. 454072109 Page 3 of 5 Item 1(a) Name of Issuer: Indevus Pharmaceuticals, Inc. (the "Issuer") Item 1(b) Address of the Issuer's Principal Executive Offices: 99 Hayden Avenue Lexington, MA 02421 (617) 861-8444 Item 2(a) Name of Person Filing: This statement is filed on behalf of Lindsay A. Rosenwald, M.D. ("Dr. Rosenwald" or the "Reporting Person"). Dr. Rosenwald is an investment banker, venture capitalist and fund manager. Item 2(b) Address of Principal Business Office or, if None, Residence: The address of the principal business office of Dr. Rosenwald is 787 Seventh Avenue, 48th Floor, New York, New York, 10019. Item 2(c) Citizenship: Dr. Rosenwald is a citizens of the United States. Item 2(d) Title of Class of Securities: Common Stock (the "Shares"). Item 2(e) CUSIP Number: 454072109 Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a: This Item 3 is not applicable. Item 4. Ownership: Item 4(a) Amount Beneficially Owned: The Reporting Person may be deemed the beneficial owner of the following number of Shares: Dr. Rosenwald may be deemed the beneficial owner of 3,078,463 Shares as follows: (a) 2,147,481 Shares and options to purchase 302,501 Shares owned directly by Dr. Rosenwald and (b) 628,481 shares owned by Rivki Rosenwald, Dr. Rosenwald's wife. CUSIP No. 454072109 Page 4 of 5 Item 4(b) Percent of Class: Please see Item 11 of each cover page. Item 4(c) Number of shares as to which such person has: (i) Sole power to vote or direct the vote: Please see Item 5 of each cover page (ii) Shared power to vote or to direct the vote Please see Item 6 of each cover page (iii) Sole power to dispose or to direct the disposition of Please see Item 7 of each cover page (iv) Shared power to dispose or to direct the disposition of Please see Item 8 of each cover page
Item 5. Ownership of Five Percent or Less of a Class: This Item 5 is not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person: See Item 4(a) Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company: This Item 7 is not applicable. Item 8. Identification and Classification of Members of the Group: This Item 8 is not applicable. Item 9. Notice of Dissolution of Group: This Item 9 is not applicable. Item 10. Certification: By signing below each of the Reporting Persons certifies that, to the best of such person's knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect. Page 5 of 5 SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct, as of this December 31, 2004. LINDSAY A. ROSENWALD, M.D. By /s/ Lindsay A. Rosenwald -------------------------------------- -----END PRIVACY-ENHANCED MESSAGE-----